行情

MRNS

MRNS

Marinus Pharms
NASDAQ

实时行情|Nasdaq Last Sale

2.070
-0.070
-3.27%
盘后: 2.070 0 0.00% 16:00 01/27 EST
开盘
2.060
昨收
2.140
最高
2.130
最低
2.020
成交量
73.57万
成交额
--
52周最高
5.40
52周最低
0.7700
市值
1.79亿
市盈率(TTM)
-2.1216
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MRNS 新闻

  • 3 Top-Notch “Strong Buy” Stocks Under $3
  • TipRanks.01/20 09:37
  • Marinus Provides Business Outlook for 2020
  • GlobeNewswire.01/13 12:30
  • H.C. Wainwright Reiterates Buy on Marinus Pharmaceuticals, Raises Price Target to $6
  • Benzinga.01/10 15:34
  • Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference
  • GlobeNewswire.01/07 12:30

更多

所属板块

制药
-0.42%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

MRNS 简况

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
展开

Webull提供Marinus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。